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Abstract
The V protein of parainfluenza virus 5 (PIV5) plays an important role in the evasion of host immune responses. The V protein blocks interferon
(IFN) signaling in human cells by causing degradation of the STAT1 protein, a key component of IFN signaling, and blocks IFN-β production by
preventing nuclear translocation of IRF3, a key transcription factor for activating IFN-β promoter. Interleukin-6 (IL-6), along with tumor necrosis
factor (TNF)-α and IL-1β, is a major proinflammatory cytokine that plays important roles in clearing virus infection through inflammatory responses.
Many viruses have developed strategies to block IL-6 expression.Wild-type PIV5 infection induces little, if any, expression of cytokines such as IL-6
or TNF-α, whereas infection by a mutant PIV5 lacking the conserved C-terminal cysteine rich domain (rPIV5VΔC) induced high levels of IL-6
expression. Examination of mRNA levels of IL-6 indicated that the transcription activation of IL-6 played an important role in the increased IL-6
expression. Co-infection with wild-type PIV5 prevented the activation of IL-6 transcription by rPIV5VΔC, and a plasmid encoding the full-length
PIV5V protein prevented the activation of IL-6 promoter-driven reporter gene expression by rPIV5VΔC, indicating that the V protein played a role in
inhibiting IL-6 transcription. The activation of IL-6 was independent of IFN-β even though rPIV5VΔC-infected cells produced IFN-β. Using
reporter gene assays and chromatin immunoprecipitation (ChIP), it was found that NF-κB played an important role in activating expression of IL-6.
We have proposed a model of activating and inhibiting IL-6 transcription by PIV5.
© 2007 Elsevier Inc. All rights reserved.Keywords: PIV5; IL-6 V; Paramyxovirus; SV5; NF-kappa BIntroduction
PIV5, formerly known as simian virus 5 (SV5) (Chatzian-
dreou et al., 2004), is a prototypical member of the Rubulavirus
genus of the family Paramyxoviridae, which includes many
important human and animal pathogens such as mumps virus,
respiratory syncytial virus (RSV), Newcastle Disease virus
(NDV) and measles virus as well as emerging viruses such as
Nipah and Hendra viruses (Lamb and Kolakofsky, 2001).⁎ Corresponding author. Center of Molecular Immunology and Infectious
Disease, Department of Veterinary and Biomedical Sciences, Pennsylvania State
University, 115 Henning Bldg., University Park, PA 16802, USA. Fax: +1 814
863 6140.
E-mail address: bxh40@psu.edu (B. He).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.07.009Although PIV5 was originally isolated from cultured primary
monkey cells, its likely natural host is the dog in which it causes
kennel cough (McCandlish et al., 1978). PIV5 encodes eight
viral proteins (Lamb and Kolakofsky, 2001). Nucleocapsid
protein (NP), phosphoprotein (P) and large RNA polymerase (L)
protein are important for transcription and replication of the viral
RNA genome. The V protein plays important roles in viral
pathogenesis (details will be discussed below). The fusion (F)
protein, a glycoprotein, mediates both cell-to-cell and virus-to-
cell fusion in a pH-independent manner that is essential for virus
entry into cells. Hemagglutinin-neuraminidase (HN), another
viral glycoprotein, is also involved in virus entry and release
from the host cells. The matrix (M) protein plays an important
role in virus assembly and budding (Schmitt et al., 1999, 2002).
The small hydrophobic (SH) protein is a 44-residue hydrophobic
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N-terminus in the cytoplasm (Hiebert et al., 1988). Recombinant
PIV5 without SH (rPIV5ΔSH) induces apoptosis in L929 cells
through a tumor necrosis factor (TNF)-α mediated extrinsic
apoptotic pathway (He et al., 1998, 2001; Lin et al., 2003). SH
expressed alone can block TNF-α signaling in a reporter gene
assay (Wilson et al., 2006).
PIV5 has seven genes but encodes eight viral proteins (Lamb
and Kolakofsky, 2001). The V/P gene of PIV5 is transcribed into
both theVmRNA and the PmRNA through a process of pseudo-
templated addition of nucleotides, commonly called “RNA
editing” (Thomas et al., 1988). The V mRNA is made when the
viral RNA polymerase faithfully transcribes the V/P gene.
However, during transcription the viral RNA polymerase
complex recognizes a specific RNA sequence in the V/P gene
and occasionally inserts two non-templated G residues at the site
to generate the P mRNA. As a result, the V/P gene is transcribed
into two mRNAs at about the same level and translated into two
proteins, V and P, which share identical N-termini but have
different C-termini. The P protein is a co-factor of the viral RNA-
dependent RNA polymerase complex which contains P and L.
The V protein of PIV5, a component of PIV5 virions (∼350
molecules per virion), is a multifunctional protein. The V protein
C-terminal domain contains seven cysteine residues, resembling
a zinc finger domain, and binds atomic zinc (Liston and Briedis,
1994; Paterson et al., 1995; Steward et al., 1995; Thomas et al.,
1988). The V protein of PIV5 interacts with soluble NP (Randall
and Bermingham, 1996) and the N-terminal domain of V binds
RNA through a basic region (Lin et al., 1997). The PIV5 V
protein interacts with a cellular protein (DDB1), the 127 kDa
subunit of the damage-specific DNA-binding protein (DDB)
that is involved in damaged DNA repair. This interaction
requires the presence of the C-terminal domain of V protein (Lin
and Lamb, 2000). Expression of the PIV5 V protein, via its C-
terminal domain, slows down the cell cycle (Lin and Lamb,
2000). The V protein of PIV5 can cause degradation of STAT1
protein, an essential regulator of IFN signaling, through a
proteasome mediated pathway in human cells but not in mouse
cells (Didcock et al., 1999). It has been shown that V, DDB1,
Cul4A, STAT1 and STAT2 form a complex which is essential for
V-mediated STAT1 degradation, and V has an E3 ubiquitin
ligase activity (Andrejeva et al., 2002; Parisien et al., 2002;
Precious et al., 2005; Ulane and Horvath, 2002). In addition to
preventing IFN signaling, V can inhibit IFN-β production
through an IRF-3 dependent pathway (He et al., 2002; Poole et
al., 2002). Recently, it has been shown that V interacts with
MDA-5 and this interaction plays an important role in blocking
activation of IFN-β production (Andrejeva et al., 2004). The V
protein is also known to play an essential role in blocking
apoptosis in virus-infected cells. While the exact mechanism is
not clear, it is thought that V blocks ER-stress-induced apoptosis
and this blockage function is independent of its involvement
with IFN pathways (Sun et al., 2004). Besides playing roles in
regulating host cell functions, V also regulates viral RNA
synthesis (Lin et al., 2005).
IL-6, together with proinflammatory cytokines TNF-α and
IL-1β, plays an essential role in acute inflammatory responses ininfection and in tissue repair (Kishimoto, 2005). While IL-6
itself does not have any known anti-viral activity, IL-6 facilitates
trafficking of leukocytes to sites of infection, leading to
clearance. IL-6 also plays an essential role in eliciting adaptive
immune responses to infection: IL-6 knockout mice are
defective in the transition from innate to adaptive immunity
(Jones, 2005). Virus infections are known to activate IL-6 ex-
pression. HHV-8 activates IL-6 expression via AP1 responsive
element in the IL-6 promoter (An et al., 2002); HCVactivates IL-
6 expression through activation of toll-like receptor 4 (TLR4)
expression (Machida et al., 2006). HCMV activates IL-6 at a
transcriptional level as well as at a post-transcriptional level
(Gealy et al., 2005). Interestingly, PIV5 infection does not
induce expression of IL-6, indicating that PIV5 may encode a
protein preventing IL-6 production (Arimilli et al., 2006; Young
et al., 2006). In this work, IL-6 expression was not detected in
wild-type PIV5 infected cells but was readily detected in mutant
virus rPIV5VΔC-infected cells, which lacks the conserved C-
terminus of the V protein, suggesting that wild-type PIV5
infection prevents production of IL-6, and the V protein, through
its conserved C-terminus, plays an essential role in blocking the
expression of IL-6. The mechanisms of activation of IL-6
expression by rPIV5VΔC and the inhibition of IL-6 expression
by V have been investigated in this work.
Results
IL-6 expression in rPIV5VΔC-infected cells
Previously, a large amount of IFN-β has been detected from
cells infected by rPIV5VΔC, indicating that the V protein plays
an important role in blocking IFN-β production (He et al., 2002;
Poole et al., 2002). Subsequent studies have demonstrated that
the V protein blocks IFN-β expression through IRF3 and
MDA5 (Andrejeva et al., 2004). To examine whether the V
protein plays a role in regulating expression of other cytokines,
expression levels of IL-6, TNF-α and IL-1β, which are major
proinflammatory cytokines, were measured in mock, PIV5 or
rPIV5VΔC-infected cell media using ELISA. Interestingly,
increased production of IL-6 was observed from rPIV5VΔC-
infected cells while no detectable amount of IL-6 was seen in
the media of mock or PIV5-infected HeLa cells (Fig. 1A). No
significant differences in growth were observed between PIV5
and rPIV5VΔC in HeLa cells during the same time period (Fig.
1B). No TNF-α or IL-1βwas detected in virus or mock-infected
cells (data not shown). Thus, rPIV5VΔC, which lacks the
conserved C-terminus of the V protein, induced IL-6 expression
in HeLa cells, suggesting that the V protein played a role in
preventing expression of IL-6.
Activation of IL-6 transcription by rPIV5VΔC
To investigate the mechanism of increased IL-6 production
in rPIV5VΔC-infected cells, the levels of IL-6 mRNA were
examined using quantitative RT-PCR (qRT-PCR). Shown in
Fig. 2A, an increase in the amount of IL-6 mRNAwas detected
in rPIV5VΔC-infected cells compared with mock or PIV5-
Fig. 2. Activation of IL-6 promoter by rPIV5VΔC. (A) Levels of IL-6 mRNA in
infected cells. HeLa cells were infected with mock, PIV5 or rPIV5VΔC at 5
MOI. At 36 hpi, the cells were collected and total RNAswere purified. TheRNAs
were used for quantitative real time RT-PCR (qRT-PCR) as described inMaterials
and methods. The ratio of IL-6 mRNA to actin mRNA from mock-infected cells
was set at 1. (B) Inhibition of IL-6 mRNA levels by Actinomycin D. A549 cells
were infected as before and treated with DMSO, ActD (2.5 μg/ml), or nothing.
The mRNA levels were examined as in panel A using qRT-PCR. (C) Activation
of IL-6 promoter in a reporter gene assay. HeLa cells were transfected with
p1168hIL-6-F-Luc, which contains a firefly luciferase (F-Luc) under control of
full-length IL-6 promoter, and phTK-RL, which contains a renilla luciferase
(R-Luc) under control of HSV TK promoter. The transfected cells were then
infected with mock, PIV5 or rPIV5VΔC as before. At 1 to 2 dpi, the cells were
collected and assayed for luciferase activities as described in Materials and
methods. The luciferase activity is shown as a ratio of F-Luc to R-Luc.MK,mock
infection. Error bars are standard error of mean (SEM).
Fig. 1. Expression of IL-6 from virus-infected cells. (A). Expression levels of IL-
6 from virus-infected cells. HeLa cells were infected with mock, PIV5 or
rPIV5VΔC at 5 MOI. At different time points after infection, media from the
infected cells were collected and assayed for IL-6 using ELISA as described in
Materials and methods. Error bars are standard error of mean (SEM). (B).
Growth rates of PIV5 and rPIV5VΔC in HeLa cells. HeLa cells were infected
with PIV5 or rPIV5VΔC and collected at time points indicated. Titers of the
viruses were determined using plaque assays.
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pression by increasing the amount of IL-6 mRNA. To further
investigate the role of transcription in the activation of IL-6 by
rPIV5VΔC, actinomycin D (ActD), an inhibitor of host cell
transcription, was used. Because of ActD's cytotoxicity to HeLa
cells, A549 cells, a human lung carcinoma cells, were used for
this experiment (Fig. 2B). As expected, higher levels of IL-6
mRNA were detected in rPIV5VΔC-infected A549 cells (no
treatment or DMSO, a solvent used for ActD, treatment) (Fig.
2B), further confirming the activation of IL-6 by rPIV5VΔC in
a different cell line, A549. Addition of ActD reduced the level
of IL-6 mRNA in rPIV5VΔC-infected cells to that found in
mock or PIV5-infected cells, indicating that the transcription
activation of IL-6 by rPIV5VΔC played an important role in the
increased expression of the IL-6 gene (Fig. 2B). To further
confirm the role of transcription activation in activating ex-
pression of the IL-6 gene by rPIV5VΔC, a reporter gene
system, which contains a firefly luciferase (F-Luc) gene under
control of full-length human IL-6 promoter (p1168hIL6-F-Luc)
(Fig. 2 and Vanden Berghe et al., 1998), was used. This plasmid
was transfected into HeLa cells with a second plasmid, phTK-RL, which contains renilla luciferase (R-Luc) under control of
HSV TK promoter (Promega, Inc., Madison, WI) as an
indicator of transfection efficiency. The transfected cells were
then infected with mock, PIV5 or rPIV5VΔC at 1 day after
transfection. The cells were collected and assayed for dual
luciferase activities. Increased reporter gene expression was
Fig. 4. Activation of IL-6 expression required live virus. PIV5 or rPIV5VΔC
were UV-inactivated as described before in Sun et al. (2004). HeLa cells were
incubated with mock, PIV5, rPIV5VΔC or UV-inactivated viruses. The relative
levels of IL-6 mRNAwere measured using qRT-PCR as in Fig. 2A.
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rPIV5VΔC infection activated transcription driven by IL-6
promoter (Fig. 2C). The lower induction of the reporter gene
expression may be due to the low rate co-transfection/infection
rate of PIV5-infected and transfected cells (less than 10%) as
reported before (He et al., 2002). In addition, the reporter system
may be less sensitive. It was reported that TNF-α, a known IL-6
inducer, was able only to have three folds of the reporter gene
induction using this system (Vanden Berghe et al., 1998).
Inhibition of IL-6 expression by V
To examine whether V can block the production of IL-6 in
rPIV5VΔC-infected cells, the cells were co-infected with
rPIV5VΔC and wild-type PIV5, which expresses the full-length
V protein. As shown in Fig. 3A, rPIV5VΔC infection caused an
increase in the level of IL-6 mRNA and this increased level of
IL-6 mRNA was reduced by wild-type PIV5 co-infection,
suggesting that the full-length V protein blocked activation of
the IL-6 promoter in rPIV5VΔC-infected cells. Inhibition of theFig. 3. Inhibition of activation of IL-6. (A) Inhibition of IL-6 activation by
rPIV5VΔC by co-infection with PIV5. HeLa cells were infected with mock,
PIV5, rPIV5VΔC or various ratios of PIV5 to rPIV5VΔC. The levels of IL-6
mRNAwere measured as in Fig. 2A. MOIs used in the experiment are indicated
below the graph. (B) Inhibition of IL-6 activation by rPIV5VΔC byV. HeLa cells
were transfected with p1168hIL6-F-Luc, phTK-RL and a plasmid encoding Vor
GFP and then infected with viruses as in Fig. 2C. The luciferase activities were
measured as described before (Fig. 2C). MK, mock infection. Error bars are
standard error of mean (SEM).activation of IL-6 promoter in rPIV5VΔC-infected cells was
also examined using the reporter gene system. An expression
plasmid encoding the full-length V protein was transfected into
the cells together with p1168hIL6-F-Luc and a transfection
control plasmid. The cells were then infected with rPIV5VΔC.
Transfection with the plasmid encoding V blocked the activation
of IL-6-promoter-driven reporter gene expression induced by
rPIV5VΔC infection (Fig. 3B), indicating V inhibited the acti-
vation of IL-6 promoter by rPIV5VΔC.
Virus replication was required for activation of IL-6 expression
To examine whether virus replication is required for the
activation of IL-6 transcription by rPIV5VΔC, the ability of UV-
inactivated virus to induce IL-6 production was investigated. As
shown in Fig. 4, UV-inactivated rPIV5VΔC did not cause an
increase in IL-6 mRNA expression as measured using real time
PCR, indicating that virus replication was required for the
activation of the IL-6 promoter by rPIV5VΔC.
Activation of IL-6 expression was independent of IFN-β
It is known that rPIV5VΔC can activate expression of IFN-β
(He et al., 2002; Poole et al., 2002). Thus, it is possible that
expression of IL-6 is caused by IFN-β expression. To investigate
this possibility, production of IL-6 in U3A cells, which are
defective in STAT1 expression (McKendry et al., 1991), a vital
transcriptional factor for IFN-β signaling, was examined. The
production of IL-6 was enhanced by rPIV5VΔC infection
compared with either mock or PIV5 infection in U3A cells (Fig.
5A), indicating that IL-6 expression in rPIV5VΔC-infected cells
does not depend on STAT1-dependent IFN signaling and that
expression of IL-6 is likely independent of IFN. The effect of
anti-IFN-β antibody on the activation of IL-6 was also
examined. Even in the presence of a vast amount of anti-IFN-
β antibody, IL-6 mRNA level was increased by rPIV5VΔC
infection (Fig. 5B).
It is known that IRF-3 plays an important role in activation of
IFN-β production by rPIV5VΔC. To examine whether IRF-3
plays a role in rPIV5VΔC-activated IL-6 expression, a plasmid
Fig. 5. Activation of IL-6 was independent of IFN-β. (A) Activation of IL-6
expression in the U3A cells. The U3A cells were infected with mock, PIV5 or
rPIV5VΔC at 5 MOI as before. Media were collected from infected cells at time
points indicated. Amount of IL-6 in the media was measured using ELISA. (B)
Effect of anti-IFN-β on the activation of IL-6. HeLa cells were infected and
treated with 1 μg/ml of anti-IFN-β antibody or equal amount of control
antibody. The relative levels of IL-6 mRNAwere measured using qRT-PCR. (C)
Effect of IRF-3DN on the activation of IL-6. HeLa cells were transfected with
plasmids encoding V, VΔC, P or IRF-3DN and p1168hIL-6-F-Luc and phTK-
RL. The transfected cells were then infected with mock, PIV5 or rPIV5VΔC.
Dual luciferase assays were carried out as described in Materials and methods.
The relative luciferase activity indicates ratio of F-Luc to R-Luc. Error bars are
standard error of mean (SEM).
Fig. 6. NF-κB played an essential role in the activation of IL-6. (A) NF-κB was
required for the activation of IL-6. A reporter gene assay similar to Fig. 2Awas
used. Besides using a plasmid containing a full-length human IL-6 promoter-
driven luciferase gene (p1168hIL-6-F-Luc, IL6P-Wt in figure), an identical
plasmid except with two point mutations in the NF-κB binding site of the IL-6
promoter (pNF-κBmut-IL-6-F-Luc, IL6P-NF-κBmut in figure) or a plasmid
containing only the TATA box of the IL-6 promoter (p50hIL-6-F-Luc, IL6P
deletion in figure) was used. (B) Activation of NF-κB factors. Nuclear extract
from mock, PIV5 or rPIV5VΔC-infected HeLa cells were used in an ELISA-
based NF-κB transcription assay from Active Motif (TransAM NF-κB family
kit, Active Motif, Carlsbad, California) following manufacturer's instructions as
described in the Materials and methods. (C) ChIP of IL-6 promoter. HeLa cells
were infected with rPIV5VΔC as before and the cells were collected for ChIP as
described in Materials and methods.
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used in the reporter gene assay. As shown in Fig. 5C, IRF-3DN
did not block the activation of IL-6 promoter in rPIV5VΔC-infected cells (Fig. 5C), suggesting that IL-6 expression was
independent of IFN-β.
The role of NF-κB in the activation of IL-6 promoter by
rPIV5VΔC
The IL-6 promoter contains many binding sites for tran-
scription factors including NF-κB. It is known that NF-κB plays
an essential role in proinflammatory responses including the
267Y. Lin et al. / Virology 368 (2007) 262–272activation of IL-6 expression. To examine whether NF-κB
played a role in the activation of IL-6 by rPIV5VΔC infection, a
plasmid containing mutations in the NF-κB binding site was
used in the reporter gene assay system. As shown in Fig. 6A,
abolishing the NF-κB binding site within the IL-6 promoter
abrogated the activation of IL-6 promoter by rPIV5VΔC,
indicating that NF-κB played an essential role in the activation
of IL-6 promoter in rPIV5VΔC-infected cells. There are five
subunits of NF-κB factors. To investigate which NF-κB factor
is responsible for the activation of IL-6 promoter, activation of
NF-κB factors was examined using ELISA as described in
Fuentes et al. (2007). It was observed that rPIV5VΔC infection
activated p65, p50 and p52, to a lesser extent. To further
examine which NF-κB factor is involved in the activation of IL-
6 expression in rPIV5VΔC, association of IL-6 promoter with
individual NF-κB factors was examined using chromatin
immunoprecipitation (ChIP). As shown in Fig. 6C, anti-p50
antibody precipitated the most IL-6 promoter, a finding that is
consistent with the possibility that p50 played a role in the
activation of IL-6 promoter by rPIV5VΔC. Interestingly, anti-
p52 also precipitated a low level IL-6 promoter-containing
DNA.
Effect of V on TNF-α and LPS-induced NF-κB activation
To examine whether the V protein could block the activation
of the IL-6 promoter by other stimuli other than virus infection
such as LPS, an LPS-responsive system (HEK 293 cells
containing TLR4) was employed. The V protein expression had
no effect on LPS-activated IL-6 promoter-driven reporter gene
expression, indicating that the V protein does not block LPS-
activated IL-6 expression (Fig. 7A). To examine whether the V
protein could block the activation of NF-κB factor by stimuli
such as TNF-α, a reporter gene assay was used. The V protein
had no effect on TNF-α-induced activation of NF-κB (Fig. 7B),
in contrast to the SH protein of PIV5, which is known to inhibit
TNF-α-mediated NF-κB activation (Wilson et al., 2006).Fig. 7. Effects of the V protein on IL-6 activation by LPS and NF-κB activation by
expressing TLR4 were transfected with plasmids encoding V, P, SH or GFP and plasm
cells were then treated with LPS for 16 h and assayed for luciferase activities as descri
TNF-α. L929 cells were transfected with plasmids encoding V, P, SH or GFP and
treated with TNF-α for 16 h and assayed for luciferase activities. The relative luciferas
(SEM).Discussion
Here, we provide evidence that the PIV5 V protein prevents
the induction of IL-6 expression in PIV5-infected cells as IL-6
expression was induced on infection with a recombinant virus
lacking the cysteine-rich C-terminus of V protein, but was not
induced on infection with wt virus harboring full-length V
protein. Previously, a mutant PIV5, CPI−, was reported to
induce expression of IL-6 (Arimilli et al., 2006; Young et al.,
2006). However, because mutations in the CPI− virus V/P gene
are located in the shared region that encodes both V protein and P
protein, it was not clear whether increased expression of IL-6
was caused bymutation to Vor to P or to both. It was also unclear
whether the increased IL-6 expression resulted from a loss of
function of the V protein to inhibit IL-6 expression, or a gain of
function by the mutant V protein or the mutant P protein to
activate IL-6 expression. In this study, we used a mutant PIV5
that lacks the conserved C-terminus of the V protein, but has no
changes to the amino acid sequence of P protein. This virus
induced IL-6 expression. Thus, the increased expression of IL-6
in this case can be directly attributed to the V protein. To
determine whether IL-6 expression is blocked by wt V protein or
alternatively is induced by the truncated VΔC protein, we tested
the ability of full-length V protein, expressed either through co-
infection with wild-type PIV5 or via an expression plasmid, to
block production of IL-6 resulting from PIV5 VΔC infection. In
both cases, the full-length V protein was effective in preventing
IL-6 expression in PIV5 VΔC-infected cells, indicating that the
V protein functions to block production of IL-6. Strahle et al.
have reported that different strains of Sendai virus have different
abilities to induce IL-6 expression (Strahle et al., 2003).
Interestingly, the main differences among these Sendai virus
strains include changes in the V protein. Thus, it is possible that
the V protein also plays a role in Sendai virus-induced IL-6
expression. It is tempting to speculate that all paramyxoviruses
may have developed means to prevent IL-6 expression and that
the V proteins may play an important role in this process.TNF-α. (A) Effect of the V protein on IL-6 activation by LPS. 293 cells stably
ids p1186hIL-6-F-Luc, phTK-RL and a plasmid encoding CD14. The transfected
bed in Materials and methods. (B) Effect of the V protein on NF-κB activation by
plasmids pNF-κB-TATA-F-Luc and phTK-RL. The transfected cells were then
e activity indicates ratio of F-Luc to R-Luc. Error bars are standard error of mean
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viral replication process activate IL-6 expression. While it is not
known at present which viral protein activated IL-6 expression,
or alternatively whether viral RNA synthesis activated IL-6
expression, it is clear that NF-κB factor played an essential role
in the activation of IL-6 expression because mutant IL-6
promoter without an NF-κB binding site was not activated by
rPIV5VΔC infection. Nuclear factor κB (NF-κB) is a family of
transcription factors that binds to a specific DNA sequence. NF-
κB plays important roles in inflammatory and innate immune
responses (Ghosh et al., 1998; Karin et al., 2002). The family of
NF-κB includes NF-κB1 (p105), NF-κB2 (p100), Rel A (p65),
Rel B and c-Rel which can be divided into two classes dependent
on their transactivation properties and mode of synthesis. p65
has the strongest transactivation domain and p65 is responsible
for most of NF-κB transcriptional activities. p65, Rel B and c-
Rel are translated as mature forms and contain a Rel-homology
domain (RHD) that is essential for dimerization and DNA
binding at their N-termini and a transactivation domain at their
C-termini. p105 and p100 that contain RHD domain at their N-
termini and ankyrin repeats at their C-termini are precursors for
p50 and p52 respectively. The precursors undergo ubiquitin-
dependent proteolysis to remove the C-terminal domains to
generate p50 and p52 which only have the RHD domain that
enables them to dimerize and to bind DNA but lack the C-
terminal transactivation domain. Interestingly, two structurally
similar NF-κB factors, p50 and, to a lesser extent, p52 were
found to be associated with the IL-6 promoter in rPIV5VΔC-
infected cells. Previously, it has been reported that p65 is
activated in L929 cells infected with PIV5 lacking the SH gene
(rPIV5ΔSH) (Lin et al., 2003). In this work, p50 of NF-κB was
associated with the IL-6 promoter in rPIV5VΔC-infected HeLa
cells, indicating that p50 of NF-κB played a role in activating IL-
6 expression. It is not clear how p50 or p52 activates IL-6
transcription since neither has an activation domain. While NF-
κB factors are required for activation of IL-6 expression, they
may not be sufficient. It is known that different stimuli activate
IL-6 expression differently through activation of different tran-
scription factors. For instance, TNF-α activates IL-6 expression
through activation of NF-κB factors and C/EBP factors (Vanden
Berghe et al., 1999). IL-1 activates IL-6 expression through NF-
IL6 factor (also known as C/EBP-β) (Akira et al., 1990). While
mutations of NF-κB binding site in IL-6 promoter resulted in
reduction of IL-6 promoter activity without reducing the basal
expression level of the IL-6-driven reporter (Fig. 6A), further
deletion of the promoter resulted in a severe reduction in IL-6
driven reporter gene expression, suggesting that promoter ele-
ments in addition to the NF-κB site are important for IL-6
expression. Previously, it was shown that rPIV5VΔC activates
IFN-β expression as well as NF-κB factors (He et al., 2002;
Poole et al., 2002). It is not surprising that activation of IL-6 and
IFN-β occurs in different ways. IRF3 plays an essential role in
activating IFN-β expression but did not affect IL-6 expression.
IFN-β promoter contains an IRF3 binding site while IL-6
promoter does not. Activation of IL-6 by rPIV5VΔC relied on
p50 of NF-κB, but not p65, the strongest NF-κB factor. It
is likely that other transcription factors are activated inrPIV5VΔC-infected cells, leading to an enhanced expression
of IL-6. Further studies on the activation of NF-κB factors and
their role in the production of IL-6 have the potential to provide
new knowledge relevant to paramyxovirus pathogenesis.
Whereas the V protein blocked rPIV5VΔC-activated IL-6
expression, interestingly it had no effect on LPS-activated IL-6
production or TNF-α-activated NF-κB activity, indicating that
the V protein blocked a virus-specific pathway leading to NF-κB
activation and IL-6 expression. Many NF-κB target genes,
including IL-6, are important for host defense against virus
infection. Therefore, it is not surprising that many viruses have
developed means to block NF-κB activation at various stages of
NF-κB activation cascades (Tato and Hunter, 2002). Because the
V protein did not affect the activation of IL-6 promoter by LPS,
or the activation of NF-κB by TNF-α, we speculate that the V
protein blocks a step in the pathway upstream of NF-κB
activation. However, it is possible that the activation of NF-κB
by LPS or TNF-α is different from that caused by rPIV5VΔC
infection and that the V protein blocks a step downstream of
NF-κB activation that is critical for virus-stimulated induction,
but not for LPS or TNF-α-mediated induction.
Materials and methods
Plasmids
pIRF3-DN was generated from a plasmid encoding IRF3-
GFP (a gift from Dr. Peter Howley and Ronco et al., 1998) by
deleting N-terminal residues of IRF3 following description by
Lin et al. (1999) using standard molecular cloning techniques.
phTK-RL, which contains a modified renilla luciferase gene
with potential enhancer elements changed within its coding
sequence under control of TK promoter of HSV, was from
Promega (Madison, WI). pNF-κB-TATA-F-Luc, which contains
NF-κB binding sites and firefly luciferase gene, was described
before by Sun et al. (1994). p1168hIL-6-F-Luc, which contains
full-length human IL-6 promoter and reporter gene firefly
luciferase under its control, p50hIL-6-F-Luc, which contains
only the TATA box region of the IL-6 promoter, and phIL-6-NF-
κBmut-F-Luc, which contains the full-length IL-6 promoter
with two point mutations in the NF-κB binding site, were
described by Vanden Berghe et al. (1999, 1998). pCD14, which
expresses CD14, was described in Chow et al. (1999).
Expression vector pCAGGS was first described by Niwa et al.
(1991). pCAGGS-V, pCAGGS-P and pCAGGS-GFP were
described before (Lin et al., 1998, 2005; Waning et al., 2002).
Plasmids were prepared using QiaGenMaxiprep kit according to
manufacturer's protocol (Valencia, CA).
Viruses and cells
The PIV5 lacking the conserved C-terminus of the V protein
(rPIV5VΔC) was first described in He et al. (2002). The virus
was amplified in Vero cells as described before (He et al., 2002).
To ensure the validity of the virus used, RNA from the virus-
infected cells was purified and viral genome sequence of the V/P
gene was determined using RT-PCR sequencing. When the
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infected cells, the virus was then used in the experiments. Wild-
type PIV5 was grown in MDBK cells as described before
(Paterson and Lamb, 1993). Titers of the viruses were
determined using plaque assay with BHK cells.
HeLa, A549, MDBK and U3A were maintained in Dulbec-
co's modified Eagle's medium (DMEM) (Invitrogen) with 10%
fetal bovine serum (FBS), 100 I.U./ml penicillin and 100 μg/ml
streptomycin at 37 °C with 5%CO2. BHK cells were maintained
in the same media plus 10% tryptose phosphate. 293T-TLR4
cells were maintained in the same media as HeLa cells plus
0.4 μg/ml G418 (Genetecin, Invitrogen Inc., San Diego, CA) to
maintain TLR4 expression as described in Chow et al. (1999).
After infection, FBS concentration was reduced to 2%.
ELISA
Amount of IL-6 protein inmedia was measured using ELISA.
Ninety-six-well plate was coated with reconstituted mouse anti-
human IL-6 mAb (#MAB206, R&D Systems, Minneapolis,
MN) at 500 μg/ml in buffer containing 0.1 M NaHCO3, pH 8.2
in a humidified container and incubated overnight at 4 °C. The
plate was washed 4 times with PBST (0.5% TWEEN-20 in
phosphate-buffered saline, PBS, pH 7.0). The plate was then
blocked with 200 μl of 1% bovine serum albumin (BSA) in PBS
for at least 2 h at room temperature and washed 3 times with
PBST, pH 7.0. Samples, as well as standards and blanks in
volume of 100 μl were added to the plate. IL-6 standards ranging
from 10,000 to 9.8 pg/ml were obtained by 1:1 series dilution
using recombinant human IL-6 (rh IL-6, #206-IL, R&D
Systems). The plate was incubated inside a humidified container
overnight at 4 °C. The plate was then washed 4 times with PBST,
pH 7.0 and the reconstituted biotinylated affinity purified goat
anti-human IL-6 pAb (R&D Systems #BAF206) in Tris-
buffered saline at 50 μg/ml in 1% BSA/PBS were added. The
plate was then incubated for 2 h at room temperature and washed
6 times with PBST, pH 7.0. Streptavidin peroxidase at 1 μg/ml in
PBS was added to the plate and the plate was incubated for 30
min at room temperature. The plate was washed 6 times with
PBST, pH 7.0 and 100 μl of the ABTS/peroxide substrate
solution (150 mg of 2,2′-Azino-bis(3-ethylbenzthiazoline-6-
sulfonic acid, Sigma) to 500ml of 0.1M citric acid and adjust pH
to 4.35 with NaOH) was added to each well. The plate was
incubated for 60 to 90 min at room temperature in the dark and
read at a wavelength of 405 nm using a plate reader.
Quantitative RT-PCR
Monolayer of HeLa or A549 cells in 6 cm dishes was washed
with PBS and inoculated with mock, rPIV5 and rPIV5VΔC
viruses in DMEM with 1% bovine serum albumin (BSA) at a
multiplicity of infection (MOI) of 5 for 1 to 2 h at 37 °C. Cells
were then washed and incubated in DMEM with 2% FBS at
37 °Cwith 5%CO2. At indicated time points post infection, cells
were lysed, total RNA extracted with RNeasy Mini Kit (Qiagen)
and eluted in RNase-free H2O. RNA concentration was
determined by using a spectrophotometer. Five hundred nano-grams of total RNA for each sample was used for reverse
transcription with random primers (Applied Biosystems) and
Superscricpt III reverse transcriptase (Invitrogen) according to
manufacturer's protocol. Eight percent of the cDNA from each
sample was then used for real time PCR reaction. Real time PCR
was carried out on ABI 7300 Real Time PCR System using
Taqman Universal PCR Master Mix (Applied Biosystems) and
pre-validated Taqman Gene Expression Assays kit (Applied
Biosystems), with human IL-6 (Assay ID: Hs00174131_m1) as
target gene and human beta actin as endogenous control
(Applied Biosystems 4326315E). Each sample was done in
triplicates. Results were analyzed with RQ study software
(Applied Biosystems). TheΔΔCT method recommended by the
manufacturer (Applied Biosystems) was used to compare the
relative expression levels of IL-6 mRNA. Expression of IL-6
gene was normalized based on the levels of mRNA for human
beta actin. The normalized IL-6 expression level of mock-
infected cells was set as 1, to which the expression levels of
samples were compared and then presented as fold changes.
UV inactivation of the viruses was carried out as before (Lin
et al., 2003; Sun et al., 2004). Viruses were placed in 3.5 cm
dishes with lids removed inside a Fisher Hamilton Biological
Safety cabinet Class II and were UV irradiated for 30 min before
inoculation. Cells were then washed and incubated in the UV-
inactivated media at 37 °C with 5% CO2. In samples that were
further treated with other reagents, the DMEM with 2% FBS
was supplemented with DMSO, or 2.5 μg/ml Actinomycin D
(A. G. Scientific, San Diego, CA); 1 μg/ml normal goat IgG
(Santa Cruz Biotechnology, Santa Cruz, CA); or 1 μg/ml anti-
interferon β antibody (Sigma, St. Louis, MO).
Dual luciferase reporter gene assay
HeLa cells were seeded in 96-wellMicroClear plates (Greiner
Bio-One) at about 1:3 dilution. Cells at about 80–90% con-
fluence were transfected (about 16 to 21 h after passage). Opti-
MEM medium (0.3 ml) was mixed with 12 μl Fugene 6
transfection reagent (Roche Diagnostics, Indianapolis, IN) at
room temperature for 5 min. DNA was added to each mixture
and incubated at room temperature for 15 min. Plasmid amounts
were as follows: 0.06 μg phTK-RL with 4.68 μg p1168hIL-6-F-
Luc, 4.68 μg p50hIL-6-F-Luc, or 4.68 μg phIL-6-NF-κBmut-F-
Luc. To transfect cells, 12 μl mixture was added to each well of
24 wells in 96-well plate. For transfection with pCAGGS-V or
pIRF3DN, amount of IL-6-reporter plasmid was reduced to
accommodate the addition of pCAGGS-Vor other plasmids. The
ratio of pCAGGS-V or other plasmids expressing GFP or
IRF3DN to p1168hIL6P-Luc was 3 to 1. For virus infection,
media were aspirated 24 h after transfection and then transfected
cells were infected with mock, wild-type, or rPIV5VΔC virus in
DMEM plus 1% BSA at 3 MOI for 1 h at 37 °C plus 5% CO2.
Media were then changed to DMEM plus 2% FBS, and
incubation was continued at 37 °C plus 5% CO2. Luciferase
assays were carried out at 24 to 48 h after infection. Media were
aspirated and cells were lysed in 30 μl 1× Passive Lysis Buffer
(Promega, Madison, WI). Thirty microliters of Luciferase Assay
Buffer II mixed with Luciferase Assay substrate (Promega) was
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plate Luminometer.
NF-κB assays and ChIP
HeLa cells were infected at an MOI of 3. One day post-
infection cells were trypsonized and washed with PBS without
calcium or magnesium, counted and 2×106 cells were used for
the nuclear extraction. Cells were pelleted at 1000 rpm for 5 min
at 4 °C and resuspended in 400 μl of cold buffer A (10 mM
HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA,
1 mM DTT and 0.5 mM phenylmethylsulfonyl fluoride) and
incubated for 15 min on ice. Twenty five microliters of 10%
IGEPAL was added to the tubes, the cells were vortexed for 15 s
and centrifuged at 1000 rpm for 5 min at 4 °C. The pellet was
washed with cold buffer A and finally resuspended in 100 μl of
cold buffer C (20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1 mM DTT, 1 mM phenylmethylsulfonyl
fluoride). Nuclear extract was incubated at 4 °C overnight and
the debris was pelleted at 14,000 rpm for 5 min. Supernatants
were frozen at −80 °C until use. Amount of protein in the extract
was measured using the BCA Protein Assay reagent kit from
PIERCE (PIERCE, Rockford, IL) according to the manufac-
turer's instructions. To examine activation of the p65, p50 and
p52 subunits of NF-κB the Active Motif TransAM NF-κB
family kit (Active Motif, California, Cat no. 43296) was used
according to the manufacturer's recommendations. One micro-
gram of protein was added to the wells of a 96-well plate coated
with immobilized oligonucleotide containing the NF-κB con-
sensus site (5′-GGGACTTTCC-3′). After a 1 h incubation
period at room temperature the wells were washed 3 times with
the washing buffer included on the kit and 100 μl of the provided
anti-p65, anti-p50 or anti-p52 antibodies was added at a 1:1000
dilution. The plate was incubated at room temperature for 1 h and
the wells were washed 3 times. HRP-conjugated anti-rabbit IgG
was added at a 1:1000 dilution and incubated for 1 h at room
temperature. Cells were washed 4 times and developing solution
was added, followed by the stop solution. The amount of p65,
p50 or p52 activation was measured at 405 nm in an HTS 700
BioAssay reader (Perkin Elmer, Norwalk, CT).
To examine association of transcription factors NF-κB and
IL-6 promoter, ChIP was used following standard ChIP
procedure. HeLa cells (3×107) (in six T150 flasks) were
infected by rPIV5VΔC at MOI of 5 for 2 h. At 24 hpi, the cells
were digested with trypsin+EDTA for 10 min and then 20 ml of
10% formaldehyde was added to each T150 to cross-link the
cells at room temperature for 10min. Glycine was added tomake
the final concentration at 0.1 M and the cells were incubated at
room temperature for 5 min. The cells were then collected,
washed with PBS and then lysed with cell lysis buffer (5 mM
Pipes (KOH), pH 8.0/85 mM KCl/0.5% NP-40) containing
1 mM PMSF on ice for 10 min. To remove the supernatant, the
cell lysate were spun at 5000 rpm for 5 min in a tabletop
centrifuge. The pellet was resuspended in nuclear lysis buffer
(50 mM Tris, pH 8.1/10 mM EDTA/1% SDS) and incubated on
ice for 10 min. Chromatin was then sonicated to an average
length of about 600 bp using a Branson Sonifier 250 at 3–4output, 90% duty cycle, 5 s for six times while keeping samples
on ice. After sonication, the samples were spun using a tabletop
centrifuge at 14,000 rpm for 1 min to remove debris and then
diluted in CHIP dilution buffer (0.01% SDS/1.1% Triton-X-100/
1.2 mM EDTA/16.7 mM Tris, pH 8.1/167 mM NaCl plus 1 mM
PMSF). The sample was then divided into seven fractions, one
was saved for use as total input control and the others were
incubated with 8 μg of rabbit IgG, anti-p65, anti-p50, anti-p52,
Rel-B and c-Rel (Santa Cruz Biotechnology). At the same time
Sepharose-A beads were added and incubated at 4 °C overnight.
The Sepharose-A beads were then washed with: low salt wash
buffer (0.1% SDS/1% Triton X-100/2 mM EDTA, 20 mM Tris,
pH 8.1/150 mM NaCl) once, high salt wash buffer (0.1% SDS/
1% Triton-X-100, 2 mM EDTA, 20 mM Tris, pH 8.1, 500 mM
NaCl) once, and LiCl wash buffer (0.25 M LiCl/1% NP-40/1%
deoxycholate, 1 mM EDTA/10 mM Tris, pH 8.0) once. After
washing, the beads were treated with 250 μl fresh-made elution
buffer (1% SDS/0.1 M NaHCO3) and incubated at 65 °C for
15 min. One microliter of RNase (10 mg/ml) in 0.3 M NaCl was
added to the sample and the sample was incubated at 65 °C for 4
h to reverse cross-linking. Afterwards, 2 volumes of 100%
ethanol were added to precipitate the DNA overnight. The DNA
was spun down, resuspended and treated with protease K at
45 °C for 1 h. DNA was then cleaned up using Qiagen PCR
purification kit. To detect the presence of IL-6 promoter in the
processed sample, PCR reactions were carried out using forward
primer: 5′ gcgctagcctcaatgacgacctaag 3′; reverse primer: 5′
gtcctatatttattgggggttgag 3′, which are specific for human IL-6
promoter. PCR reactions were performed at 94 °C for 45 s, 55 °C
for 45 s and 72 °C for 45 s for 40 cycles. The PCR products were
resolved in 1% agarose gel.
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